Significantly greater reductions seen in signs and symptoms of moderate-to-severe atopic dermatitis at week 12 compared with placebo
Vivek Murthy Confirmed as New US Surgeon General
Murthy plans to focus on COVID-19, mental health, and substance use disorders
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Alopecia areata (AA) is an autoimmune form of hair loss with limited treatments.To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and brepocitinib in patients with AA …
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with …
Mohs surgery for early-stage Merkel cell carcinoma (MCC) achieves local control better than wide local excision ± radiation therapy with no increase in MCC-specific death.
Merkel cell carcinoma (MCC) of the skin is most commonly treated with wide local excision (WLE) with or without adjuvant radiation therapy (RT). Mohs micrographic surgery (MMS) as monotherapy may …
Toxic Epidermal Necrolysis Like Lupus – A Case Series.
Extensive epidermal loss is not a commonly recognised presentation of acute cutaneous lupus; however, when it does occur, it can be life-threatening and mimic Stevens Johnson Syndrome or Toxic Epidermal …